drugset / Trial / NCT01700400
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase 1
Completed
13 enrolled
Cancer Research and Biostatistics Clinical Trials Consortium
Novartis Pharmaceuticals · collabProvidence Cancer Center, Earle A. Chiles Research Institute · collabUniversity of Arizona · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether the investigational study drug everolimus may be used to increase the effectiveness of chemotherapy treatment for patients with advanced lung cancer.
Timeline
- Start
- 2012-09
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Everolimus | Small molecule | 2.5 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |